top of page

Newsroom

Reflecting on Myeloma Awareness Month

As we near the end of March, we want to take the time to commemorate Myeloma Month and reflect on the impact of this disease on individuals, families and communities.


What is Myeloma?

Myeloma, also known as multiple myeloma, is a type of blood cancer affecting the bone marrow's plasma cells. According to a Leukemia and Myeloma Research study, "Approximately 5,700 people are diagnosed with myeloma yearly in the UK alone".

The effects of myeloma can be devastating, with the disease often affecting multiple parts of the body, such as the spine, skull, pelvis and ribs. It can cause bone pain, fatigue, kidney problems and infections, among other symptoms. However, there is hope for those who have been diagnosed with myeloma. Treatments for myeloma can effectively control the disease, relieve its symptoms and complications, and prolong life.


What are we doing to help?

At Genefirst, we are passionate and unwavering in our mission to end Myeloma. As a result, we designed our XCeloSeq Myeloid Fusion Kit with this purpose at its core. We hope that with proper usage, this kit could play a crucial role in fighting myeloma.

So how does it work? First, the kit has a pool of specific RNA enrichment primers. These primers identify known and unidentified fusions from RNA samples. These primers have been specifically designed for use with XCeloSeq Targeted RNA Core Reagents (GF031). Together they allow for the generation of high-quality, high-complexity sequencing libraries suitable for use with Illumina® next-generation sequencing instruments.

The XCeloSeq Myeloid Fusion Kit is a groundbreaking tool that we can use to study the genetic mutations of myeloma and develop new treatments. By accelerating our understanding of this life-threatening illness, physicians and researchers have an opportunity to create more effective therapies for those suffering from it—which is why it's so essential we spread awareness!


How Can you Help?

In addition to promoting the use of the XCeloSeq Myeloid Fusion Kit, we must continue to support the ongoing research and advocacy efforts to improve the lives of those affected by myeloma. By working together, we can advance our understanding of this disease and develop better ways to diagnose, treat, and cure it.


Let's take this Myeloma Month as an opportunity to educate ourselves and others about this disease. To learn more about the kit and how we can use it in the fight against myeloma, click to view our factsheet. Alternatively, you can get in touch with our experts here!


Additionally, if you would like to participate in any fundraising initiatives Leukemia and Myeloma Research is running this month, please visit their website.


Together, we can make a difference in the fight against myeloma!

bottom of page